Skip to main content

Legacy & Low-Evidence Classes

Agents historically used in reconstructive and functional urology whose evidence base has not held up, whose mainstream use has been superseded, or that survive only in niche / specialty / international practice. Documented here for completeness, historical awareness, and for the rare refractory scenario where they remain relevant.

The point of this section is stewardship: surgeons should know what has been tried and what has not worked, what remains in older guidelines but has been quietly de-prescribed, and what to recognize on a patient's medication list when reviewing prior care.

  • ImipramineThe only FDA-approved TCA for urology (childhood enuresis). Five-mechanism table including vasopressin-independent antidiuretic effect; Kornholt 2019 negative SUI RCT; positioned vs the broader TCAs hub.
  • ParasympathomimeticsLegacy / specialty companion to the Cholinergic Agonists hub. Historical Bethanechol Supersensitivity Test, Riedl 2000 electromotive test, 2025 pyridostigmine RCTs, Japan's distigmine — agents that remain in regional practice.
  • PhenazopyridineTRPM8 mechanism (Luyts 2023); the 2-day rule to avoid masking infection; G6PD + methemoglobinemia + methylene-blue antidote paradox cross-link. Symptomatic-only — not a UTI treatment.
  • PhytotherapyFour-agent framework (saw palmetto / β-sitosterol / pumpkin seed / Pygeum); negative CAMUS trial vs the positive Vela-Navarrete hexanic-Permixon signal; three counseling scenarios for the BPH patient who arrives already on a supplement.